Kronos Bio, Inc.Kronos Bio, Inc.Kronos Bio, Inc.

Kronos Bio, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪85.94 M‬USD
−2.00USD
‪−112.67 M‬USD
‪6.29 M‬USD
‪38.29 M‬
Beta (1Y)
2.38

About Kronos Bio, Inc.

CEO
Norbert W. Bischofberger
Headquarters
San Mateo
Employees (FY)
63
Founded
2017
FIGI
BBG00L072923
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of KRON is 1.44 USD — it has increased by 0.70% in the past 24 hours. Watch Kronos Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kronos Bio, Inc. stocks are traded under the ticker KRON.
KRON stock has risen by 20.00% compared to the previous week, the month change is a 37.14% rise, over the last year Kronos Bio, Inc. has showed a 30.10% decrease.
We've gathered analysts' opinions on Kronos Bio, Inc. future price: according to them, KRON price has a max estimate of 6.00 USD and a min estimate of 2.25 USD. Watch KRON chart and read a more detailed Kronos Bio, Inc. stock forecast: see what analysts think of Kronos Bio, Inc. and suggest that you do with its stocks.
KRON reached its all-time high on Nov 24, 2020 with the price of 39.60 USD, and its all-time low was 0.69 USD and was reached on May 24, 2024. View more price dynamics on KRON chart.
See other stocks reaching their highest and lowest prices.
KRON stock is 8.96% volatile and has beta coefficient of 2.38. Track Kronos Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kronos Bio, Inc. there?
Today Kronos Bio, Inc. has the market capitalization of ‪85.94 M‬, it has increased by 9.57% over the last week.
Yes, you can track Kronos Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Kronos Bio, Inc. is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
KRON earnings for the last quarter are −0.50 USD per share, whereas the estimation was −0.42 USD resulting in a −18.34% surprise. The estimated earnings for the next quarter are −0.36 USD per share. See more details about Kronos Bio, Inc. earnings.
Kronos Bio, Inc. revenue for the last quarter amounts to ‪2.52 M‬ USD, despite the estimated figure of ‪1.00 M‬ USD. In the next quarter, revenue is expected to reach ‪1.53 M‬ USD.
KRON net income for the last quarter is ‪−29.96 M‬ USD, while the quarter before that showed ‪−25.32 M‬ USD of net income which accounts for −18.32% change. Track more Kronos Bio, Inc. financial stats to get the full picture.
No, KRON doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 15, 2024, the company has 63.00 employees. See our rating of the largest employees — is Kronos Bio, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kronos Bio, Inc. EBITDA is ‪−106.21 M‬ USD, and current EBITDA margin is ‪−1.81 K‬%. See more stats in Kronos Bio, Inc. financial statements.
Like other stocks, KRON shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kronos Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kronos Bio, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kronos Bio, Inc. stock shows the buy signal. See more of Kronos Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.